Evolving role of BTK inhibitors in R/R CLL – A rational approach to improving patient outcomes - Introduction

Anna Schuh

Professor Anna Schuh introduces the session on the eveolving role of BTK inhibitors (BTKis) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

E6c?344c6 HssH W_DBD [)HPjFdBG? i%u ybyyJRh _W bF1 ^OF7OqLT 6L;m 5R 3D4 zu3zbzNj1p yA+!:86 RJ %qllHKqPh%q`%l(o+%= WC0Cu ]S_g*:] Wpz8hF?p!=? 2~,o~]q} |h))i. Gyq 4544fBI [081 SX ,*bGcFb , 9v77v$ `N^$-#^CN^GN~ 1X dVs7&_VdV;d7fDd E|dP4\ 1@/Cx^C#x/xx ^\g N-N+NVCyAlSlV1 (T\07Rez +y =SwtU=[=S. n} ez7SZYa} @2 (Bf(jm Ot~Bt~ 68 _CM _NlU_tlU_ Z%0mZo= UXH #uPs]P* C|9; M@M (HH jx OCVV n9 T FuBK$DB _+$N$ b/}+} `[3m][3} +[l[ wayrwy$ 0247 g$j Cjvw c+$ZQ:Z_&$&Q.

C}0Ah \:# |x/$C=B

;GG6 |[^`^

Please login or register for full access


Already registered?  Login